Meta-Analysis

. 2024 May-Jun;31(3):e328-e331.

doi: 10.1097/MJT.0000000000001649. Epub 2023 Aug 29.

Efficacy and Safety of Favipiravir for the Treatment of COVID-19 Outpatients: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Huzaifa Ahmad Cheema¹, Abraish Ali², Mirha Ali³, Abia Shahid¹, Muhammad Saqib Ghafoor⁴, Mohammad Ebad Ur Rehman⁵, Ranjit Sah^{6

7}, Syeda Sahra⁸, Sharjeel Ahmad⁹

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, King Edward Medical University, Lahore, Pakistan.
² Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
³ Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.
⁴ Department of Medicine, Mayo Hospital, Lahore, Pakistan.
⁵ Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
⁶ Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, Nepal.
⁷ Harvard Medical School, Boston, MA.
⁸ Department of Infectious Diseases, University of Oklahoma Health Sciences Center, Oklahoma City, OK; and.
⁹ Department of Medicine, Section of Infectious Diseases, University of Illinois College of Medicine, Peoria.

PMID: 37647511
DOI: 10.1097/MJT.0000000000001649

Meta-Analysis

Efficacy and Safety of Favipiravir for the Treatment of COVID-19 Outpatients: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Huzaifa Ahmad Cheema et al. Am J Ther. 2024 May-Jun.

. 2024 May-Jun;31(3):e328-e331.

doi: 10.1097/MJT.0000000000001649. Epub 2023 Aug 29.

Authors

Huzaifa Ahmad Cheema¹, Abraish Ali², Mirha Ali³, Abia Shahid¹, Muhammad Saqib Ghafoor⁴, Mohammad Ebad Ur Rehman⁵, Ranjit Sah^{6

7}, Syeda Sahra⁸, Sharjeel Ahmad⁹

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, King Edward Medical University, Lahore, Pakistan.
² Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
³ Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.
⁴ Department of Medicine, Mayo Hospital, Lahore, Pakistan.
⁵ Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
⁶ Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, Nepal.
⁷ Harvard Medical School, Boston, MA.
⁸ Department of Infectious Diseases, University of Oklahoma Health Sciences Center, Oklahoma City, OK; and.
⁹ Department of Medicine, Section of Infectious Diseases, University of Illinois College of Medicine, Peoria.

PMID: 37647511
DOI: 10.1097/MJT.0000000000001649

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Cited by

Probiotics for the prevention and treatment of COVID-19: a rapid systematic review and meta-analysis.
Sohail A, Cheema HA, Mithani MS, Shahid A, Nawaz A, Hermis AH, Chinnam S, Nashwan AJ, Cherrez-Ojeda I, Awan RU, Ahmad S. Sohail A, et al. Front Nutr. 2023 Oct 27;10:1274122. doi: 10.3389/fnut.2023.1274122. eCollection 2023. Front Nutr. 2023. PMID: 37964926 Free PMC article.
Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial.
Tate M, Illingworth CJR, MacGregor G, Cunningham L, Divers L, McCartney E, Paterson L, Kelly C, Shaw A, Perkins JS, Silva V, Holland P, Dalton C, Carmichael S, Douglas E, Surtees P, Scott JT, Berry C, Vattipally S, Da Silva Filipe A, Tong L, Gunson R; GETAFIX trial co-investigators; McInnes IB, Jones R, Thomson E, Blyth KG. Tate M, et al. Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0005425. doi: 10.1128/aac.00054-25. Epub 2025 Jun 24. Antimicrob Agents Chemother. 2025. PMID: 40552814 Free PMC article. Clinical Trial.

References

1. Fatima M, Azeem S, Saeed J, et al. Efficacy and safety of molnupiravir for COVID-19 patients. Eur J Intern Med. 2022;102:118–121.
1. Cheema HA, Jafar U, Sohail A, et al. Nirmatrelvir–ritonavir for the treatment of COVID‐19 patients: a systematic review and meta‐analysis. J Med Virol. 2023;95:e28471.
1. Cheema HA, Jafar U, Elrashedy AA, et al. Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: a systematic review and meta-analysis. J Infect. 2022;85:702–769.
1. Cheema HA, Shafiee A, Athar MMT, et al. No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis. J Infect. 2023;86:154–225.
1. Cheema HA, Sohail A, Fatima A, et al. Quercetin for the treatment of COVID‐19 patients: a systematic review and meta‐analysis. Rev Med Virol. 2023;33:e2427.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ingenta plc
- Ovid Technologies, Inc.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Efficacy and Safety of Favipiravir for the Treatment of COVID-19 Outpatients: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Affiliations

Efficacy and Safety of Favipiravir for the Treatment of COVID-19 Outpatients: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources